Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€157.30

€157.30

-2.650%
-4.26
-2.650%
€181.51
 
24.04.26 / Tradegate WKN: 789617 / Symbol: BIIB / Name: Biogen / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Biogen Inc. Stock

We can see a decrease in the price for Biogen Inc.. Compared to yesterday it has lost -€4.260 (-2.650%).
With 29 Buy predictions and not a single Sell prediction Biogen Inc. is an absolute favorite of our community.
As a result the target price of 181 € shows a slightly positive potential of 15.07% compared to the current price of 157.3 € for Biogen Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Biogen Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Biogen Inc. in the next few years

Pros
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Biogen Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Biogen Inc. -2.650% 4.393% -0.913% 49.881% 4.972% -40.731% -27.562%
BioMarin Pharmaceutical Inc. -1.750% -2.304% -2.848% -17.629% -10.864% -47.910% -30.243%
Zoetis Inc. A 0.240% -4.115% -0.360% -25.449% -7.116% -37.577% -29.252%
Elanco Animal Health Inc. -0.780% -2.370% -8.937% 135.986% -0.885% 110.958% -26.100%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-27

Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.

Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.

Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.

Comments

Prediction Buy
Perf. (%) -
Target price 203.014
Change
Ends at 25.04.27

Biogen (BIIB) had its price target raised by The Goldman Sachs Group, Inc. from $231.00 to $238.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -3.24%
Target price 191.588
Change
Ends at 22.04.27

Biogen (BIIB) was upgraded by UBS Group AG from "neutral" to "buy". They now have a $225.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 5.01%
Target price 184.735
Change
Ends at 07.04.27

Biogen (BIIB) had its price target lowered by Royal Bank Of Canada from $233.00 to $213.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Show more

News

Why Biogen Stock Got Mashed on Monday: https://g.foolcdn.com/editorial/images/864251/healthcare-professional-inspecting-charts.jpg
Why Biogen Stock Got Mashed on Monday

Healthcare company Biogen (NASDAQ: BIIB) wasn't looking very healthy on the stock market on Monday. Investors traded out of its shares after learning that the company plans to book a hefty charge in

Why Biogen Stock Sank While the Market Soared on Thursday: https://g.foolcdn.com/editorial/images/863638/person-checking-medicine-on-a-shelf-in-a-pharmacy.jpg
Why Biogen Stock Sank While the Market Soared on Thursday

Bullishness was in the air on the stock market on Tuesday, but you'd hardly know that from the performance of Biogen (NASDAQ: BIIB). The healthcare sector mainstay saw its share price slump by over

Why Biogen Stock Surged Almost 9% Higher on Friday: https://g.foolcdn.com/editorial/images/855338/person-in-a-lab-gazing-into-a-microscope.jpg
Why Biogen Stock Surged Almost 9% Higher on Friday

One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both